Evidence map›Paper›PMID 32155324›Full record

ArticleJournal of cellular and molecular medicine2020

Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.

Fabienne Kellner, Andreas Keil, Katrin Schindler, Todor Tschongov, Kerstin Hünninger, Hannah Loercher, Peter Rhein, Sylvia-Annette Böhmer, Frank-D Böhmer, Jörg P Müller

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Fabienne KellnerInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Andreas KeilInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Katrin SchindlerInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Todor TschongovInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Kerstin HünningerFungal Septomics, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.
Hannah LoercherInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Peter RheinLuminex B.V., 's-Hertogenbosch, The Netherlands.
Sylvia-Annette BöhmerInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Frank-D BöhmerInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Jörg P MüllerInstitute for Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.ORCID 0000-0003-0223-6781
Jena University Hospital · DELeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DELuminex (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Class III receptor tyrosine kinases control the development of hematopoietic stem cells. Constitutive activation of FLT3 by internal tandem duplications (ITD) in the juxtamembrane domain has been causally linked to acute myeloid leukaemia. Oncogenic FLT3 ITD is partially retained in compartments of the biosynthetic route and aberrantly activates STAT5, thereby promoting cellular transformation. The pool of FLT3 ITD molecules in the plasma membrane efficiently activates RAS and AKT, which is likewise essential for cell transformation. Little is known about features and mechanisms of FLT3 ligand (FL)-dependent internalization of surface-bound FLT3 or FLT3 ITD. We have addressed this issue by internalization experiments using human RS4-11 and MV4-11 cells with endogenous wild-type FLT3 or FLT3 ITD expression, respectively, and surface biotinylation. Further, FLT3 wild-type, or FLT3 ITD-GFP hybrid proteins were stably expressed and characterized in 32D cells, and internalization and stability were assessed by flow cytometry, imaging flow cytometry, and immunoblotting. FL-stimulated surface-exposed FLT3 WT or FLT3 ITD protein showed similar endocytosis and degradation characteristics. Kinase inactivation by mutation or FLT3 inhibitor treatment strongly promoted FLT3 ITD surface localization, and attenuated but did not abrogate FL-induced internalization. Experiments with the dynamin inhibitor dynasore suggest that active FLT3 as well as FLT3 ITD is largely endocytosed via clathrin-dependent endocytosis. Internalization of kinase-inactivated molecules occurred through a different yet unidentified mechanism. Our data demonstrate that FLT3 WT and constitutively active FLT3 ITD receptor follow, despite very different biogenesis kinetics, similar internalization and degradation routes.

Indexed as

CarcinogenesisCell Transformation, Neoplasticfms-Like Tyrosine Kinase 3Gene DuplicationGene Expression Regulation, NeoplasticHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteLigandsMembrane ProteinsMutationSTAT5 Transcription FactorTandem Repeat Sequencesflt3 ligand proteinFLT3 protein, humanfms-Like Tyrosine Kinase 3LigandsMembrane ProteinsSTAT5 Transcription FactordegradationFms-like tyrosine kinase 3 internal tandem duplicationsGFP hybrid genesoncogeneplasma membranereceptor endocytosisreceptor tyrosine kinase

Identifiers

PMID32155324
PMCPMC7176853
OpenAlexW3012225568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.